Geode Capital Management LLC Buys 130,213 Shares of Cencora, Inc. (NYSE:COR)

Geode Capital Management LLC raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,326,064 shares of the company's stock after buying an additional 130,213 shares during the period. Geode Capital Management LLC owned 2.24% of Cencora worth $969,471,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora in the fourth quarter valued at $30,000. Kentucky Trust Co bought a new position in shares of Cencora in the 4th quarter valued at about $33,000. Householder Group Estate & Retirement Specialist LLC grew its position in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the period. Finally, WASHINGTON TRUST Co increased its stake in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Activity at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now directly owns 317,913 shares of the company's stock, valued at $85,680,732.63. This trade represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock valued at $8,034,778 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Remove Ads

Cencora Stock Performance

NYSE COR traded down $10.07 on Friday, reaching $279.29. The stock had a trading volume of 4,404,535 shares, compared to its average volume of 1,469,415. The firm has a fifty day moving average of $256.66 and a two-hundred day moving average of $242.38. The company has a market cap of $54.16 billion, a P/E ratio of 39.73, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $297.46. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is currently 31.29%.

Analysts Set New Price Targets

A number of equities analysts recently commented on COR shares. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Wells Fargo & Company raised their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average price target of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.